Harmony Biosciences Holdings, Inc. - COMMON STOCK (HRMY) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
HRMY on Nasdaq
Shares outstanding
57,644,670
Price per share
$37.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
49,792,301
Total reported value
$1,862,570,821
% of total 13F portfolios
0%
Share change
+2,403,655
Value change
+$92,861,949
Number of holders
315
Price from insider filings
$37.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Harmony Biosciences Holdings, Inc. - COMMON STOCK (HRMY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Marshman Fund Trust II 11% $178,084,462 6,051,120 Marshman Fund Trust II 31 Dec 2024
BlackRock, Inc. 10% -18% $169,781,023 -$35,290,072 5,768,978 -17% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 8.3% $139,310,113 4,733,609 The Vanguard Group 31 Dec 2024
FMR LLC 5.4% -19% $116,481,431 -$27,472,267 3,112,812 -19% FMR LLC 31 Dec 2025

As of 31 Dec 2025, 315 institutional investors reported holding 49,792,301 shares of Harmony Biosciences Holdings, Inc. - COMMON STOCK (HRMY). This represents 86% of the company’s total 57,644,670 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Harmony Biosciences Holdings, Inc. - COMMON STOCK (HRMY) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 7,088,688 +2.3% 0% $265,258,704
VANGUARD GROUP INC 8.4% 4,813,357 -5.6% 0% $180,115,819
FMR LLC 5.4% 3,112,812 -19% 0.01% $116,481,430
AMERICAN CENTURY COMPANIES INC 3.2% 1,841,672 +10% 0.03% $68,915,366
DIMENSIONAL FUND ADVISORS LP 3.2% 1,830,726 +8.2% 0.01% $68,506,807
STATE STREET CORP 2.9% 1,661,850 +0.5% 0% $62,186,427
LSV ASSET MANAGEMENT 2.9% 1,657,093 +3.9% 0.14% $62,008,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.6% 1,491,605 +15% 0.03% $55,815,859
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,270,586 +0.98% 0% $47,551,305
RENAISSANCE TECHNOLOGIES LLC 1.9% 1,070,471 -5.9% 0.06% $40,057,025
SG Americas Securities, LLC 1.7% 961,667 +4102% 0.05% $35,986,000
MORGAN STANLEY 1.4% 817,506 -3.6% 0% $30,591,084
AQR CAPITAL MANAGEMENT LLC 1.4% 813,889 +129% 0.02% $30,455,726
Boston Partners 1.2% 708,943 -6% 0.03% $26,367,837
GOLDMAN SACHS GROUP INC 0.99% 569,362 -12% 0% $21,305,526
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 0.94% 541,281 -5.1% 0.01% $20,254,735
BNP PARIBAS FINANCIAL MARKETS 0.91% 525,145 0% 0.01% $19,650,926
NOMURA HOLDINGS INC 0.88% 510,024 +17% 0.14% $19,085,098
ARMISTICE CAPITAL, LLC 0.87% 500,000 0.46% $18,710,000
venBio Partners LLC 0.85% 489,194 0% 8.5% $18,305,639
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 0.8% 459,134 +73% 0.02% $17,180,794
Invesco Ltd. 0.78% 450,805 +12% 0% $16,869,123
CITADEL ADVISORS LLC 0.73% 420,410 +518% 0.01% $15,731,743
NORTHERN TRUST CORP 0.73% 418,938 -3.2% 0% $15,676,660
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.73% 417,955 -8.4% 0% $15,639,876

Institutional Holders of Harmony Biosciences Holdings, Inc. - COMMON STOCK (HRMY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 49,792,301 $1,862,570,821 +$92,861,949 $37.42 315
2025 Q3 47,339,126 $1,304,886,690 -$112,498,749 $27.56 292
2025 Q2 51,269,247 $1,620,478,469 +$22,306,889 $31.60 276
2025 Q1 50,193,424 $1,664,235,088 -$100,697,267 $33.19 267
2024 Q4 52,708,406 $1,813,638,877 +$62,320,767 $34.41 244
2024 Q3 50,136,635 $2,005,018,440 +$11,121,046 $40.00 231
2024 Q2 50,163,988 $1,513,604,428 +$34,652,893 $30.17 218
2024 Q1 48,982,561 $1,644,752,000 +$41,053,934 $33.58 206
2023 Q4 47,832,583 $1,544,993,160 -$51,074,763 $32.30 219
2023 Q3 49,527,453 $1,623,105,557 -$85,461,798 $32.77 203
2023 Q2 51,951,129 $1,828,229,880 +$28,751,282 $35.19 207
2023 Q1 51,270,566 $1,674,006,219 -$29,571,258 $32.65 213
2022 Q4 51,015,535 $2,810,596,096 +$34,893,529 $55.10 238
2022 Q3 50,461,165 $2,237,024,113 +$91,703,030 $44.29 195
2022 Q2 47,874,920 $2,335,182,718 +$99,684,851 $48.77 173
2022 Q1 45,933,803 $2,235,023,234 +$79,981,090 $48.65 168
2021 Q4 44,541,354 $1,899,444,678 +$107,131,256 $42.64 138
2021 Q3 30,932,269 $1,185,850,908 +$116,456,188 $38.33 99
2021 Q2 27,994,218 $790,282,400 -$7,611,822 $28.23 79
2021 Q1 27,468,517 $907,561,000 -$18,485,709 $33.04 55
2020 Q4 27,956,363 $998,030,405 -$18,654,367 $36.15 59
2020 Q3 28,549,056 $940,508,000 +$940,508,000 $33.90 44